Start here if you're new
what it is
This company is trying to turn radioactive cancer drugs into real treatments, and right now you are buying the attempt.
how it gets paid
Last year Catx made $2M in revenue.
what just happened
The key takeaway was another quarterly loss, with latest-quarter EPS at -$0.89 on essentially no revenue.
At a glance
B balance sheet — gets the job done, barely
45/100 earnings predictability — expect surprises
-$0.98 fy2024 eps est
$2B fy2026 rev est
1.2 beta
xvary composite: 48/100 — below average
What they do
This company is trying to turn radioactive cancer drugs into real treatments, and right now you are buying the attempt.
The edge is focus. CATX has 140 employees and only two named lead programs, so your bet is concentrated on a small set of shots on goal. Precision-targeted alpha therapies (radioactive drugs aimed at tumors) → cancer treatment with a guided warhead → if the data works, tiny companies can suddenly matter.
How they make money
$2M
annual revenue
total revenue
$2M
n/a
The products that matter
pre-revenue cancer drug development
Targeted Alpha Therapies
$2M revenue · no approved products
this pipeline carries the whole $570M valuation while the company currently reports just $2M in revenue. Until something gets approved, the product is really a sequence of trial milestones.
pipeline
Key numbers
$0.98
FY2024 EPS
EPS (earnings per share) → profit or loss for each share → you are still funding losses, not buying current earnings.
$2B
FY2026 revenue
Revenue estimate → expected sales → this is the dream case sitting next to $0M of trailing revenue.
$3M
long-term debt
Long-term debt → money owed over years → the balance sheet is light on debt, so the main risk is execution, not leverage.
5/100
price stability
Price stability → how steady the stock tends to trade → this score says your seatbelt matters.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $3M (0% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for CATX right now.
source: institutional data · return history unavailable
What just happened
reported a loss
The key takeaway was another quarterly loss, with latest-quarter EPS at -$0.89 on essentially no revenue.
Quarterly EPS in FY2024 ran -$0.20, -$0.17, -$0.21, and -$0.40, for a full-year estimate of -$0.98. This is what a clinical-stage biotech looks like when the science is ahead of the sales.
$0M
revenue
$0.89
eps
n/a
n/a
the number that mattered
TTM revenue is still $0M, which means the income statement is driven by research spending and financing capacity, not customer demand.
source: EDGAR and quarterly EPS history, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk here is pipeline failure in Targeted Alpha Therapies. With no approved products and just $2M in revenue, a bad clinical outcome would hit the entire equity story.
med
Clinical trial failure
There is no approved-product cushion here. If a key study disappoints, the reason for a $570M market cap gets weaker fast.
Impact: this is the core asset base. A failed readout would pressure sentiment, financing options, and valuation at the same time.
med
Cash burn and dilution
A company with $2M in revenue funds itself primarily through capital, not operations. The February 2026 $175M stock offering bought runway, but it also diluted existing owners.
Impact: even if the science works, repeated equity raises can cap per-share upside because the pie gets split more ways.
med
Institutional selling
Institutions sold 6.6M shares worth about $19M over the last 24 months. That does not decide the thesis, but it does tell you sponsorship has not been steadily building.
Impact: weak sponsorship can amplify downside when clinical or financing headlines disappoint.
A forced rerating would not need much. At $570M of market value on $2M of revenue, negative trial news or more dilution can reset the story very quickly.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
feb 17 business update
This is the next scheduled moment for management to explain what the pipeline looks like after the $175M raise.
financing
Use of proceeds from the offering
A $175M raise only helps if you can see where it goes. Watch for concrete clinical milestones, not generic runway language.
risk
Any change in trial momentum
With no approved products, a single meaningful setback can matter more than an entire quarter of financial statements.
trading
Whether sponsorship improves
Institutions were net sellers of 6.6M shares worth about $19M over 24 months. You want to see that trend stop getting worse.
Analyst rankings
earnings predictability
45 / 100
in human-speak, analysts do not have a steady operating model to lean on here. Expect estimate swings.
beta
1.2
Beta measures market sensitivity. CATX has historically moved a bit more than the market, which is normal for a speculative biotech.
risk rank
3
That places it around the middle of the pack on this system, but the operating reality is still binary because approval risk dominates.
source: institutional data
Institutional activity
institutional ownership data for CATX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$5
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive